Trial Profile
A pre-exposure prophylaxis (PrEP) clinical trial of leronlimab (PRO 140) in subjects at high risk of HIV infection
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 30 Mar 2022 According to a CytoDyn media release, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Leronlimab HIV program.The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved
- 30 Mar 2022 Status changed from planning to suspended, according to a CytoDyn media release.
- 27 Jan 2020 According to a CytoDyn media release, the company expects to initiate the trial in 2020.